Michael J. Currens - Concepedia

Author

Michael J. Currens

Also Known As

M CURRENS, M Currens, M J Currens, M. J. CURRENS, MICHAEL J. CURRENS, Michael Currens, Michael J Currens, Michael J. Currens

Publications

4.7K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute Frederick National Laboratory for Cancer Research Drug Discovery Laboratory (Norway)Science Applications International Corporation (United States)Cancer Research Center

About

Michael J. Currens is an author at National Cancer Institute specializing in medicine, hiv, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	3.7K
2	Natural Sciences	6	6	2.7K
3	Biochemistry	5	5	3.2K
4	Biomolecular Engineering	3	3	298
5	Biology	1	1	58

Michael J. Currens

Publications

4.5K

Citations

H-Index

Page 1

	Year	Citations
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Dominic A. Scudiero, Robert H. Shoemaker, Kenneth D. Paull, PubMed Chemoprevention StrategyPathologyCell CultureMetronomic ChemotherapyCell Growth	1988	2.4K
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development Michael R. Boyd, Kirk R. Gustafson, James B. McMahon, Antimicrobial Agents and Chemotherapy Viral ReplicationImmunologyEscherichia ColiAntiviral DrugSimian Immunodeficiency Virus	1997	607
HIV inhibitory natural products. Part 7. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum Yoel Kashman, Kirk R. Gustafson, Ray W. Fuller, Journal of Medicinal Chemistry	1992	546
Michellamine B, a novel plant alkaloid, inhibits human immunodeficiency virus-induced cell killing by at least two distinct mechanisms James B. McMahon, Michael J. Currens, Robert J. Gulakowski, Antimicrobial Agents and Chemotherapy Distinct MechanismsBiochemistryHiv Life CycleMedicineHuman Retrovirus	1995	125
Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase Paul L. Boyer, Michael J. Currens, James B. McMahon, Journal of Virology ImmunologyMolecular BiologyAntiviral DrugChemical BiologyDrug Resistance	1993	124
Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors Amnon Hizi, R. Tal, M Shaharabany, Antimicrobial Agents and Chemotherapy Complementary SegmentsImmunologyMolecular BiologyAntiviral DrugDrug Resistance	1993	87
Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1. Michael J. Currens, Robert J. Gulakowski, Jennifer Mariner, Journal of Pharmacology and Experimental Therapeutics	1996	72
Analysis of the Interaction between the HIV-Inactivating Protein Cyanovirin-N and Soluble Forms of the Envelope Glycoproteins gp120 and gp41 Barry R. O’Keefe, Shilpa R. Shenoy, Dong Xie, Molecular Pharmacology	2000	71
Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups R W Buckheit, Walter J. Decker, J. Alan Roberson, Antiviral Research Distinct Phenotypic SubgroupsHuman RetrovirusImmunologyAntiviral Drug DevelopmentResistance Mutation (Virology)	1995	63
Isolation and Characterization of <i>Myrianthus holstii</i> Lectin, a Potent HIV-1 Inhibitory Protein from the Plant <i>Myrianthus holstii</i> Romila D. Charan, Murray H. G. Munro, Barry R. O’Keefe, Journal of Natural Products ImmunologyMolecular BiologyAntiviral DrugAfrican Plant MyrianthusHuman Retrovirus	2000	58

Page 1